171 related articles for article (PubMed ID: 19010845)
1. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
Micha D; Cummings J; Shoemaker A; Elmore S; Foster K; Greaves M; Ward T; Rosenberg S; Dive C; Simpson K
Clin Cancer Res; 2008 Nov; 14(22):7304-10. PubMed ID: 19010845
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Cummings J; Hodgkinson C; Odedra R; Sini P; Heaton SP; Mundt KE; Ward TH; Wilkinson RW; Growcott J; Hughes A; Dive C
Mol Cancer Ther; 2008 Mar; 7(3):455-63. PubMed ID: 18347133
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
[TBL] [Abstract][Full Text] [Related]
4. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Dean EJ; Cummings J; Roulston A; Berger M; Ranson M; Blackhall F; Dive C
Neoplasia; 2011 Apr; 13(4):339-47. PubMed ID: 21472138
[TBL] [Abstract][Full Text] [Related]
5. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.
Olofsson MH; Cummings J; Fayad W; Brnjic S; Herrmann R; Berndtsson M; Hodgkinson C; Dean E; Odedra R; Wilkinson RW; Mundt KE; Busk M; Dive C; Linder S
Cancer Biomark; 2009; 5(3):117-25. PubMed ID: 19407366
[TBL] [Abstract][Full Text] [Related]
6. Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.
Mattoo AR; FitzGerald DJ
Int J Cancer; 2013 Feb; 132(4):978-87. PubMed ID: 22821746
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.
Risberg K; Fodstad Ø; Andersson Y
PLoS One; 2011; 6(9):e24012. PubMed ID: 21915275
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
Zinn RL; Gardner EE; Dobromilskaya I; Murphy S; Marchionni L; Hann CL; Rudin CM
Mol Cancer; 2013 Mar; 12():16. PubMed ID: 23452820
[TBL] [Abstract][Full Text] [Related]
9. Secreted Heat Shock Protein 90α Attenuated the Effect of Anticancer Drugs in Small-Cell Lung Cancer Cells Through AKT/GSK3β/β-Catenin Signaling.
Du Y; Wu J; Luo L
Cancer Control; 2018; 25(1):1073274818804489. PubMed ID: 30282477
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
Hou JM; Greystoke A; Lancashire L; Cummings J; Ward T; Board R; Amir E; Hughes S; Krebs M; Hughes A; Ranson M; Lorigan P; Dive C; Blackhall FH
Am J Pathol; 2009 Aug; 175(2):808-16. PubMed ID: 19628770
[TBL] [Abstract][Full Text] [Related]
12. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.
Kim KW; Moretti L; Mitchell LR; Jung DK; Lu B
Clin Cancer Res; 2009 Oct; 15(19):6096-105. PubMed ID: 19773376
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
[TBL] [Abstract][Full Text] [Related]
14. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
Song JH; Kandasamy K; Kraft AS
J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
[TBL] [Abstract][Full Text] [Related]
15. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
Kim EY; Jung JY; Kim A; Chang YS; Kim SK
Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
[TBL] [Abstract][Full Text] [Related]
16. A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers.
Simpson KL; Cawthorne C; Zhou C; Hodgkinson CL; Walker MJ; Trapani F; Kadirvel M; Brown G; Dawson MJ; MacFarlane M; Williams KJ; Whetton AD; Dive C
Cell Death Dis; 2013 May; 4(5):e613. PubMed ID: 23640455
[TBL] [Abstract][Full Text] [Related]
17. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
18. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P; Chao BH; Litz J; Krystal GW
Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.
Yu X; Dobrikov M; Keir ST; Gromeier M; Pastan IH; Reisfeld R; Bigner DD; Chandramohan V
PLoS One; 2019; 14(1):e0210608. PubMed ID: 30625226
[TBL] [Abstract][Full Text] [Related]
20. ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-ras Mutant Non-Small Cell Lung Cancer Preclinical Model.
Lee JM; Kim HS; Kim A; Chang YS; Lee JG; Cho J; Kim EY
Yonsei Med J; 2022 Jan; 63(1):16-25. PubMed ID: 34913280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
